1. For patients requiring repeat (elective or urgent) revascularization during the study, reloading the patient with elinogrel/placebo IV bolus (Kit A ±X) and the clopidogrel/placebo loading dose (Kit C) should be performed. 2. To ensure consistent antiplatelet coverage during the transition to open-label therapy at the end of study participation, a regimen for clopidogrel reloading was recommended. 3. The timing of the second oral dose of elinogrel (Kit B) was updated to ensure that patients receive their second dose in the evening of their index PCI. 4. The treatment period for chronic oral dosing was extended from 60 days to 120 days; patients who are currently active on the study at the time of approval of the amendment will have the option to sign a new consent form in order to participate for the extended period of 120 days. Corresponding Day 120 endpoints were added to assess efficacy and safety. 5. An administrative interim analysis after all patients have completed the first 60 days of treatment was added. 6. Inclusion criterion #3 was modified to require two forms of contraception, one of which must consist of oral or injected contraceptives, transdermal hormone patch, subdermal implants, IUD with hormones or copper, or surgical sterilization. 7. Exclusion criterion #11 regarding administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g., warfarin) within the 7 days prior to PCI was modified to also exclude patients with a requirement for chronic oral anticoagulation. 8. At the recommendation of the DSMC, the 50 mg dose level was dropped from randomization on April 8, 2009.